Medpace/$MEDP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Medpace
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Ticker
$MEDP
Sector
Primary listing
Employees
6,000
Headquarters
Website
Medpace Metrics
BasicAdvanced
$13B
35.42
$13.46
1.47
-
Price and volume
Market cap
$13B
Beta
1.47
52-week high
$501.30
52-week low
$250.05
Average daily volume
356K
Financial strength
Current ratio
0.427
Quick ratio
0.348
Long term debt to equity
72.495
Total debt to equity
86.934
Profitability
EBITDA (TTM)
506.477
Gross margin (TTM)
68.51%
Net profit margin (TTM)
18.74%
Operating margin (TTM)
21.40%
Effective tax rate (TTM)
15.56%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
17.09%
Return on equity (TTM)
89.38%
Valuation
Price to earnings (TTM)
35.423
Price to revenue (TTM)
6.46
Price to book
77.49
Price to tangible book (TTM)
-25.49
Price to free cash flow (TTM)
24.864
Free cash flow yield (TTM)
4.02%
Free cash flow per share (TTM)
19.172
Growth
Revenue change (TTM)
9.94%
Earnings per share change (TTM)
26.42%
3-year revenue growth (CAGR)
20.16%
3-year earnings per share growth (CAGR)
32.76%
What the Analysts think about Medpace
Analyst ratings (Buy, Hold, Sell) for Medpace stock.
Bulls say / Bears say
Medpace increased its full-year revenue forecast by $280 million at the midpoint to $2.42 billion–$2.52 billion, citing better client funding and fewer project cancellations (Reuters).
Q2 2025 revenue rose 14.2% year-over-year to $603.3 million, beating analyst estimates, with a net book-to-bill ratio of 1.03x signaling strong new business wins (Reuters via TradingView).
The company repurchased 1.75 million shares for $518.5 million in Q2 2025, with $826.3 million left under its buyback program, showing strong cash generation and a commitment to returning value to shareholders (Reuters via TradingView).
Analysts warn that demand for clinical trials has not fully rebounded, and ongoing headwinds could limit Medpace’s future revenue growth (Reuters).
Q2 net income margin fell from 16.7% to 15.0% year-over-year, affected by higher direct costs and SG&A expenses (Reuters via TradingView).
Jefferies reiterated a Hold rating and kept its $285 price target after Q2 results, highlighting continued valuation concerns and sector headwinds (Barron's).
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
Medpace Financial Performance
Revenues and expenses
Medpace Earnings Performance
Company profitability
Medpace News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Medpace stock?
Medpace (MEDP) has a market cap of $13B as of September 11, 2025.
What is the P/E ratio for Medpace stock?
The price to earnings (P/E) ratio for Medpace (MEDP) stock is 35.42 as of September 11, 2025.
Does Medpace stock pay dividends?
No, Medpace (MEDP) stock does not pay dividends to its shareholders as of September 11, 2025.
When is the next Medpace dividend payment date?
Medpace (MEDP) stock does not pay dividends to its shareholders.
What is the beta indicator for Medpace?
Medpace (MEDP) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.